XBIO logo

Xenetic Biosciences, Inc.


XBIO: Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer.


Show XBIO Financials

Consumer Interest
SEC Filings

Recent trades of XBIO by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by XBIO's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Compositions and methods for administering insulin or insulin-like protein to the brain Jan. 29, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of XBIO in WallStreetBets Daily Discussion


Recent insights relating to XBIO

CNBC Recommendations

Recent picks made for XBIO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in XBIO

Corporate Flights

Flights by private jets registered to XBIO